TNDM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tandem Diabetes Care Inc (TNDM) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows some positive catalysts, the financial performance and technical indicators suggest caution. The stock may require further stabilization before being considered a solid long-term investment.
The MACD is negatively expanding (-0.137), indicating bearish momentum. RSI at 33.237 is neutral but approaching oversold territory. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below key support levels (S1: 22.019, S2: 20.022), suggesting potential further downside.
Hedge funds are significantly increasing their positions, with an 870.81% increase in buying activity.
Analysts have raised price targets, with some projecting significant upside (e.g., Lake Street's $50 target).
Expansion of diabetes management technology to Android smartphones could increase market share.
The stock is down 4.56% in regular market trading, indicating weak short-term sentiment.
Financial performance in Q4 2025 showed a significant drop in net income (-178.01% YoY) and EPS (-200.00% YoY).
Competitive pressures and uncertainty in the transition to the PayGo model remain concerns.
In Q4 2025, revenue increased by 2.74% YoY to $290.38M, and gross margin improved to 57.67%. However, net income dropped significantly (-178.01% YoY), and EPS declined by 200.00%, reflecting profitability challenges.
Analysts are mixed but leaning positive. Several firms have raised price targets, with notable upgrades from Lake Street ($50) and Barclays ($56). However, many maintain Neutral or Hold ratings, citing near-term uncertainties despite long-term growth potential.
